Table 4.
Comparison of molecular profile of each intrinsic subtype
|
ER/PR + HER2- |
ER/PR + HER2+ |
HER2 type |
Basal-like |
Unclassified |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | OR | n | OR | n | OR | n | OR | n | OR | |
|
EGFR | ||||||||||
| Positive |
16 |
1.0 (Ref) |
5 |
2.77 (0.69, 9.44) |
19 |
9.64 (3.76, 20.53) |
34 |
104.55 (41.51, 856.77) |
0 |
0.00 (0.00, 2.75) |
| Negative |
283 |
|
35 |
|
39 |
|
3 |
|
28 |
|
|
PTEN | ||||||||||
| Reduced |
156 |
1.0 (Ref) |
18 |
0.75 (0.35, 1.55) |
16 |
0.31(0.16, 0.63) |
28 |
2.57 (1.11, 6.37) |
16 |
1.31 (0.55, 3.15) |
| Normal |
140 |
|
23 |
|
42 |
|
9 |
|
12 |
|
|
Bcl-2 | ||||||||||
| Positive |
249 |
1.0 (Ref) |
27 |
0.41 (0.19, 0.99) |
7 |
0.02 (0.01, 0.07) |
6 |
0.04 (0.01, 0.12) |
14 |
0.20 (0.08, 0.49) |
| Negative |
51 |
|
13 |
|
51 |
|
31 |
|
14 |
|
|
c-Kit | ||||||||||
| Positive |
15 |
1.0 (Ref) |
0 |
0.00 (0.00, 2.16) |
7 |
2.70 (0.84, 7.48) |
10 |
7.50 (2.60, 20.96) |
1 |
0.73 (0.02, 5.29) |
| Negative |
287 |
|
41 |
|
51 |
|
27 |
|
27 |
|
|
c-Met | ||||||||||
| Positive |
203 |
1.0 (Ref) |
34 |
1.98 (0.79, 5.54) |
47 |
2.63 (1.14, 6.70) |
28 |
1.43 (0.61, 3.60) |
16 |
0.58 (0.23, 1.44) |
| Negative |
89 |
|
7 |
|
8 |
|
9 |
|
11 |
|
|
Survivin | ||||||||||
| Positive |
240 |
1.0 (Ref) |
34 |
1.32 (0.50, 4.20) |
56 |
7.54 (1.74, 61.08) |
30 |
1.25 (0.05, 3.52) |
23 |
1.41 (0.46, 4.91) |
| Negative | 62 | 6 | 2 | 7 | 5 | |||||
Results are odds ratio (OR) adjusted by age and 95% confidence interval.
EGFR: epidermal growth factor receptor, PTEN: phosphatase and tensin homolog deleted on chromosome 10, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor.